COLO.B.DK

694.2

-0.46%↓

GMAB.DK

1,283.5

+0.04%↑

ZEAL.DK

458

+0.44%↑

HLUNB.DK

31.9

+0.63%↑

AMBUB.DK

114.6

+0.35%↑

COLO.B.DK

694.2

-0.46%↓

GMAB.DK

1,283.5

+0.04%↑

ZEAL.DK

458

+0.44%↑

HLUNB.DK

31.9

+0.63%↑

AMBUB.DK

114.6

+0.35%↑

COLO.B.DK

694.2

-0.46%↓

GMAB.DK

1,283.5

+0.04%↑

ZEAL.DK

458

+0.44%↑

HLUNB.DK

31.9

+0.63%↑

AMBUB.DK

114.6

+0.35%↑

COLO.B.DK

694.2

-0.46%↓

GMAB.DK

1,283.5

+0.04%↑

ZEAL.DK

458

+0.44%↑

HLUNB.DK

31.9

+0.63%↑

AMBUB.DK

114.6

+0.35%↑

COLO.B.DK

694.2

-0.46%↓

GMAB.DK

1,283.5

+0.04%↑

ZEAL.DK

458

+0.44%↑

HLUNB.DK

31.9

+0.63%↑

AMBUB.DK

114.6

+0.35%↑

Search

Novo Nordisk A-S (Class B)

Open

462.75 -1.02

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

455.2

Max

471.05

Belangrijke statistieken

By Trading Economics

Inkomsten

929M

28B

Verkoop

14B

86B

K/W

Sectorgemiddelde

20.778

63.778

EPS

6.34

Dividendrendement

3.33

Winstmarge

32.947

Werknemers

76,302

EBITDA

4.1B

39B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+9.53% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.33%

2.39%

Volgende Winsten

7 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-31B

2.1T

Vorige openingsprijs

463.77

Vorige sluitingsprijs

462.75

Novo Nordisk A-S (Class B) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 feb 2025, 15:33 UTC

Belangrijke Marktbewegers

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

5 feb 2025, 11:53 UTC

Winsten

Novo Nordisk Outlook Provides Some Welcome Relief -- 2nd Update

5 feb 2025, 08:19 UTC

Winsten

Novo Nordisk Expects Slowing Sales Growth This Year -- Update

2 apr 2025, 11:25 UTC

Marktinformatie

Novo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk

2 apr 2025, 09:27 UTC

Populaire aandelen

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

31 mrt 2025, 12:49 UTC

Marktinformatie

Novo Nordisk Had Constructive Quarter, But U.S. Volumes a Concern -- Market Talk

28 mrt 2025, 15:11 UTC

Marktinformatie

Novo Nordisk First Quarter Earnings Could Disappoint, BofA Says -- Market Talk

27 mrt 2025, 13:45 UTC

Marktinformatie
Winsten

Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk

24 mrt 2025, 10:19 UTC

Marktinformatie

Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk

24 mrt 2025, 09:08 UTC

Marktinformatie
Winsten

Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk

19 mrt 2025, 15:54 UTC

Top Nieuws

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

11 mrt 2025, 15:31 UTC

Marktinformatie

Novo Nordisk's CagriSema Trial Shows Disappointing Weight Loss -- Market Talk

11 mrt 2025, 14:58 UTC

Marktinformatie

Novo Nordisk's CagriSema Results Fail to Impress -- Market Talk

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

10 feb 2025, 12:00 UTC

Top Nieuws

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7 feb 2025, 10:30 UTC

Top Nieuws

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb 2025, 16:16 UTC

Top Nieuws
Winsten

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 feb 2025, 14:56 UTC

Winsten

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

5 feb 2025, 13:59 UTC

Winsten

Novo Nordisk Outlook Provides Some Welcome Relief -- WSJ

5 feb 2025, 12:02 UTC

Winsten

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

5 feb 2025, 11:35 UTC

Marktinformatie
Winsten

Novo Nordisk's Earnings Report Should Get It Back On Track -- Market Talk

5 feb 2025, 10:10 UTC

Populaire aandelen

Stocks to Watch Wednesday: AMD, Alphabet, Novo Nordisk -- WSJ

5 feb 2025, 09:43 UTC

Winsten

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 feb 2025, 08:47 UTC

Marktinformatie
Winsten

Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

5 feb 2025, 08:38 UTC

Marktinformatie
Winsten

Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk

5 feb 2025, 08:32 UTC

Winsten

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 feb 2025, 08:30 UTC

Marktinformatie
Winsten

Novo Nordisk Sales Guidance Materially Ahead of Expectations -- Market Talk

5 feb 2025, 06:46 UTC

Winsten

Novo Nordisk Expects to File For First Regulatory Approval of CagriSema During 1Q26

5 feb 2025, 06:45 UTC

Winsten

Novo Nordisk Plans to Initiate New CagriSema Phase 3 Trial in 2025 to Further Explore Weight Loss Potential

5 feb 2025, 06:43 UTC

Winsten

Novo Nordisk: 2025 Free Cash Flow Expected to be DKK75B-DKK85B

Peer Vergelijking

Prijswijziging

Novo Nordisk A-S (Class B) Prognose

Koersdoel

By TipRanks

9.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,162.73 DKK  9.53%

Hoogste 1,550 DKK

Laagste 720 DKK

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novo Nordisk A-S (Class B) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

7

Buy

2

Hold

2

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.